Market Place
Sourcing Support
Innate Pharma Joins D. Boral Capital Global Conference
23 Apr 2026 //
PHARMIWEB
Innate Pharma Joins Kempen Life Sciences Conference
03 Apr 2026 //
PHARMIWEB
Innate`s NK Cell Engager Latest Victim Of Pipeline Refocus
26 Mar 2026 //
FIERCE BIOTECH
Innate Pharma Announces 2025 Full-Year Results Call, Webcast
19 Mar 2026 //
PHARMIWEB
Innate Pharma Joins Leerink Partners Healthcare Conference
18 Feb 2026 //
PHARMIWEB
Innate Pharma Hosts Lacutamab Event On October 28, 2025
14 Oct 2025 //
PHARMIWEB
Innate Pharma Participates in 25th European Midcap Event
15 Sep 2025 //
PHARMAWEB
Innate Pharma to Participate in BTIG Virtual Biotech Conference
29 Jul 2025 //
BUSINESSWIRE
Innate Pharma Shows IPH6501 Activity in Lymphoma at EHA 2025
13 Jun 2025 //
BUSINESSWIRE
Innate Says Lymphoma Data Shows Anti-KIR3DL2 Antibody’s Promise
23 May 2025 //
FIERCE BIOTECH
Innate files 2024 Universal Registration Document & Annual Report
30 Apr 2025 //
BUSINESSWIRE
Innate Pharma presents preclinical data on IPH4502 at AACR 2025
29 Apr 2025 //
BUSINESSWIRE
Sanofi hands cancer drug to Innate as it pivots R&D pact focus
24 Apr 2025 //
PRESS RELEASE
Innate Pharma to Join 2025 Stifel Virtual Oncology Forum
03 Apr 2025 //
BUSINESSWIRE
Innate Pharma joins Life Sciences Van Lanschot Kempen Conference
25 Mar 2025 //
BUSINESSWIRE
Innate Pharma’s Lacutamab Gets FDA Breakthrough Therapy For SS
17 Feb 2025 //
BUSINESSWIRE
Innate Pharma Starts Phase 1 Study For IPH4502 In Advanced Tumors
27 Jan 2025 //
BUSINESSWIRE
Innate Pharma Announces Nectin-4 ADC Investor & Analyst in New York
21 Jan 2025 //
BUSINESSWIRE
Innate Pharma Secures $7.9M for IPH6501 Follicular Lymphoma Study
05 Dec 2024 //
BUSINESSWIRE
Innate Pharma Releases Its 2025 Financial Calendar
20 Nov 2024 //
BUSINESSWIRE
Innate Publishes Next-Gen ANKET® IPH6501 Data in Science Immunology
19 Nov 2024 //
BUSINESSWIRE
Innate antibody pits NK cells against lymphoma in animal models
15 Nov 2024 //
FIERCE BIOTECH
Innate Pharma Announces Q3 2024 Results & Conference Call
07 Nov 2024 //
BUSINESSWIRE
Innate Pharma Reports First Half 2024 Business Update and Financial Results
12 Sep 2024 //
BUSINESSWIRE
Innate Pharma: Monalizumab Data From NeoCOAST-2 Presented At WCLC 2024
09 Sep 2024 //
BUSINESSWIRE
Innate Pharma: Positive Phase 2 Lacutamab Data In Mycosis Fungoides
04 Jun 2024 //
BUSINESSWIRE
Innate Pharma: Clarification Regarding SAR443579 Designation
21 May 2024 //
BUSINESSWIRE
Innate: Sanofi NK Engager SAR443579 Advances To Phase 2
15 Apr 2024 //
BUSINESSWIRE
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data
06 Mar 2024 //
BUSINESSWIRE
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501
06 Mar 2024 //
BUSINESSWIRE
Innate Pharma Announces U.S. FDA Lifts Partial Hold on Lacutamab Program
04 Jan 2024 //
BUSINESSWIRE
Innate Shares Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101
11 Dec 2023 //
BUSINESSWIRE
Innate Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab
10 Dec 2023 //
BUSINESSWIRE
Innate Pharma to Host Virtual KOL Event on Lacutamab
27 Nov 2023 //
BUSINESSWIRE
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101
03 Nov 2023 //
BUSINESSWIRE
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Trial in RRMM
11 Jul 2023 //
BUSINESSWIRE
First Patient Dosed in Ph2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
26 Jun 2023 //
BUSINESSWIRE
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab
12 Jun 2023 //
BUSINESSWIRE
Innate Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501
10 Jun 2023 //
BUSINESSWIRE
Innate Highlights Ph1/2 Dose Escalation Safety of SAR’579 / IPH6101
26 May 2023 //
BUSINESSWIRE
Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress
15 May 2023 //
BUSINESSWIRE
Innate Pharma and Takeda sign licence deal to develop ADCs for coeliac disease
04 Apr 2023 //
PHARMACEUTICAL TECHNOLOGY
Innate Pharma Announces Exclusive License of Antibodies to Takeda
01 Apr 2023 //
BUSINESSWIRE
